MedTrace Logo

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT05459701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-02-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.

Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg once daily for 24 weeks.

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • University of Alexandria

    collaborator OTHER

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

  • Amira B. Kassem, Lecturer · Damanhour University

  • Yasmin Essam, Bachlor · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05459701 on ClinicalTrials.gov